Across TCGA pan-cancer cohorts, SAMD7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SAMD7 data layer compared with 19 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SAMD7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SAMD7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
BLCA, PRAD, and UCEC are the cancer types where SAMD7 Mutation most reproducibly stratifies survival.